Survodutide: The Glucagon/GLP-1 Dual Agonist for Obesity and MASH
Survodutide is an investigational glucagon/GLP-1 dual agonist showing 16-19% weight loss and significant MASH improvement in Phase 2 and 3 trials.
Survodutide: What the Research Says About This Glucagon/GLP-1 Dual Agonist Survodutide, the investigational glucagon/GLP-1 receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, is generating significant attention in metabolic medicine research. Phase 2 and Phase 3 clinical data published through mid-2026 show approximately 16-19% body weight reduction in obesity trials and striking improvements in liver disease endpoints for metabolic-associated steatohepatitis (MASH). This post breaks down what the current science shows, what survodutide's mechanism means for liver health, how it compares to other agents in the [GLP-1 space](/peptides), and what biomarkers researchers are using to track outcomes. **Important regulatory status note upfront:** Survodutide is not approved by the FDA or any regulatory authority as of mid-2026. It is available only through clinical trials. Everything discussed here reflects investigational research.
What Is Survodutide and How Does It Work?
Survodutide (research code BI 456906) is a once-weekly subcutaneous injection that simultaneously activates two receptors: the GLP-1 (glucagon-like peptide-1) receptor and the glucagon receptor. This dual mechanism is what makes it mechanistically distinct from agents like [semaglutide](/peptides/semaglutide) (GLP-1 only) and [tirzepatide](/peptides/tirzepatide) (GLP-1 plus GIP).
The GLP-1 receptor arm suppresses appetite, slows gastric emptying, and improves insulin secretion, which are the familiar mechanisms behind the entire incretin drug class.
The glucagon receptor arm is the differentiating factor. Glucagon traditionally signals the liver to release stored glucose, but sustained, pharmacologically calibrated glucagon receptor agonism in this context drives a different response: increased hepatic fat oxidation, reduced lipogenesis (fat synthesis in the liver), and elevated energy expenditure. Preclinical work on similar dual agonists has shown this hepatic glucagon signaling pathway directly reduces steatosis and improves mitochondrial function in liver tissue, independent of weight loss alone.
This combination, researchers argue, could make survodutide especially relevant for conditions where liver fat accumulation is the primary problem, such as MASH, since the drug may be working on two fronts simultaneously: reducing body weight through GLP-1 pathways while directly addressing hepatic fat through glucagon receptor engagement.
Phase 2 Obesity Trial: Nearly 19% Weight Loss at 46 Weeks
The obesity Phase 2 trial was a randomized, parallel-group, dose-finding study evaluating once-weekly subcutaneous survodutide over 46 weeks in adults with overweight or obesity without type 2 diabetes. The trial tested doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg, with 20 weeks of dose escalation followed by 26 weeks of maintenance.
At the highest dose, researchers observed approximately 19% mean body weight reduction from baseline, a result that placed survodutide among the more potent single-agent weight-loss compounds in the investigational pipeline at the time.
A post-hoc analysis published in Diabetes, Obesity and Metabolism (Roux et al., 2025) also found that survodutide was associated with meaningful reductions in blood pressure (2 to 5 mmHg systolic on average, with larger reductions in those with elevated baseline values), adding to the broader cardiometabolic profile researchers are characterizing.
Phase 2 MASH Trial: The New England Journal of Medicine Data
The most rigorous published evidence on survodutide to date for liver disease is the 48-week, randomized Phase 2 trial published in the New England Journal of Medicine in 2024 (Sanyal et al., NCT04771273). A total of 293 adults with biopsy-confirmed MASH and liver fibrosis stages F1 through F3 were assigned to survodutide at 2.4 mg, 4.8 mg, or 6.0 mg, or placebo.
Primary endpoint (histologic improvement in MASH without worsening of fibrosis):
|---|---|---|
The dose-response relationship confirmed a statistically significant signal. Secondary endpoints showed that a reduction in liver fat content of at least 30% was achieved by 57-67% of survodutide participants versus 14% on placebo. Fibrosis improvement by at least one stage was seen in 34-36% of treated participants versus 22% on placebo.
Separately, a 2024 tolerability and pharmacokinetic study in the Journal of Hepatology examined survodutide in people with cirrhosis and found clinically meaningful reductions in liver fat, liver stiffness, and biomarkers of liver fibrosis, alongside meaningful body weight reduction, with a generally tolerable safety profile.
Safety signals from the Phase 2 MASH trial: Gastrointestinal adverse events were the most common. Nausea occurred in 66% of survodutide participants versus 23% on placebo. The GI profile is similar to what is seen across the GLP-1 drug class.
FDA Breakthrough Therapy Designation for MASH
In September 2024, the FDA granted survodutide Breakthrough Therapy designation for the treatment of adults with non-cirrhotic MASH and moderate or advanced fibrosis (stages F2 to F3). This designation is intended to expedite development and review of drugs for serious conditions where preliminary evidence indicates substantial improvement over available therapy. It is not an approval and does not guarantee eventual market authorization.
Phase 3: The SYNCHRONIZE Program
Survodutide has since advanced into an extensive Phase 3 development program.
SYNCHRONIZE-1 (obesity, no type 2 diabetes, 76 weeks): Topline results released April 2026 showed 16.6% mean body weight reduction with survodutide versus 3.2% on placebo. A pre-specified body composition substudy using MRI found visceral fat reduction of up to 34% and liver fat reduction of up to 63.1% from baseline, with lean mass accounting for no more than 10.8% of total tissue mass change.
SYNCHRONIZE-MASLD (48-week trial targeting liver fat): 84.2% of survodutide participants achieved at least a 30% relative reduction in liver fat versus 24.3% on placebo. 61% achieved liver fat normalization below the 5% content threshold.
SYNCHRONIZE-2 (type 2 diabetes population) and SYNCHRONIZE-CVOT (cardiovascular outcomes trial) results are expected later in 2026. No Phase 3 results have yet been submitted for regulatory approval decisions.
How Survodutide Compares to Other Agents Researchers Track
People who follow the incretin landscape often track multiple agents over time and compare their own biomarker responses. Here is a brief orientation to where survodutide sits:
Each agent has a different receptor combination, and researchers are actively studying whether the glucagon arm in survodutide and retatrutide produces liver benefits beyond what GLP-1 or GLP-1/GIP combinations achieve. The MASH-specific data for survodutide is currently among the strongest published for any drug in its class.
What to Track: Biomarkers Relevant to Survodutide Research
One of the core principles at MyProtocolStack is that a compound is one variable. Your labs, your weight trajectory, and your metabolic markers tell the story of what is actually changing in your body over time. For people following the survodutide research, these are the biomarkers researchers use as endpoints:
Liver health markers:
Metabolic and cardiovascular markers:
Body composition: visceral fat area and lean mass percentage, which researchers are watching closely across the incretin class.
You can [track this protocol and your labs in one place](/auth/login?mode=signup) inside MyProtocolStack, logging values over time and seeing trends that a single lab draw cannot show.
Compliance, Regulatory Status, and What Survodutide Is Not
Survodutide is investigational. It does not have FDA approval for any indication as of mid-2026. Researchers are studying it, and the Phase 3 program is ongoing.
This article does not provide dosing recommendations. The FDA Breakthrough Therapy designation accelerates review; it does not signal approval or predict approval timelines. Do not use gray-market, compounded, or unverified sources of survodutide or any unapproved compound. Discuss any trial participation with a licensed hepatologist, endocrinologist, or obesity medicine specialist.
Frequently Asked Questions
What is survodutide?
Survodutide (BI 456906) is an investigational once-weekly injectable dual agonist targeting the GLP-1 receptor and the glucagon receptor. It is developed by Boehringer Ingelheim and Zealand Pharma for obesity and MASH. It is not FDA-approved.
How does survodutide differ from semaglutide or tirzepatide?
Semaglutide activates GLP-1 receptors only. Tirzepatide adds GIP receptor agonism. Survodutide pairs GLP-1 with glucagon receptor agonism, which researchers believe drives direct hepatic fat oxidation in addition to appetite suppression, making the liver-disease mechanism distinct.
What did the Phase 2 MASH trial find?
In the NEJM-published 48-week Phase 2 trial (Sanyal et al., 2024), 47-62% of survodutide participants showed histologic improvement in MASH without worsening of fibrosis versus 14% on placebo. Liver fat fell by at least 30% in 57-67% of treated participants. Fibrosis improvement by at least one stage was observed in 34-36%. These are investigational results.
What biomarkers are relevant to track alongside this research?
Researchers use ALT, AST, FIB-4 score, liver stiffness, triglycerides, HbA1c, fasting insulin, ApoB, hs-CRP, and body weight and composition. Explore the [biomarkers hub](/biomarkers) and log your own values in [MyProtocolStack](/auth/login?mode=signup) to see your trends over time.
Is survodutide available to the public?
No. Survodutide is available only via clinical trials as of mid-2026. The FDA Breakthrough Therapy designation granted in September 2024 for MASH accelerates the review process but is not an approval. Do not seek compounded or gray-market versions of unapproved drugs.
Sources
1. Sanyal AJ, et al. "A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis." New England Journal of Medicine. 2024.
2. Roux CW, et al. "Survodutide improves blood pressure in adults with obesity: A post hoc analysis of a phase 2 trial." Diabetes, Obesity and Metabolism. 2025.
3. Zafer M, et al. "GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Dual or Triple Agonists in MASLD." Alimentary Pharmacology and Therapeutics. 2025.
4. Boland ML, et al. "Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide." Nature Metabolism. 2020.
5. Boehringer Ingelheim. "Phase II Clinical Trial Weight Loss Results." 2024.
6. Boehringer Ingelheim. "Survodutide US FDA Breakthrough Therapy, Phase 3 Trials in MASH." October 2024.
7. Boehringer Ingelheim. "Survodutide Phase III SYNCHRONIZE-1 Weight Loss Results." April 2026.
8. GlobeNewswire. "Survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction." June 2026.
9. STAT News. "Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH." February 2024.
10. Journal of Hepatology. "Efficacy, tolerability and pharmacokinetics of survodutide in cirrhosis." 2024.
11. AJMC. "Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss." 2026.
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment. The content on this page is for informational purposes only and does not constitute a clinical recommendation. Survodutide is investigational and not FDA-approved. Always consult a qualified, licensed healthcare professional before starting, stopping, or adjusting any protocol or clinical trial participation.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →